产品中心
当前位置：首页>产品中心Anti-VLDL Receptor/AF350
货号： bs-4228R-AF350 基本售价： 2980.0 元 规格： 100ul
产品信息
- 产品编号
- bs-4228R-AF350
- 英文名称
- Anti-VLDL Receptor/AF350
- 中文名称
- AF350标记的极低密度脂蛋白受体抗体
- 别 名
- Very low density lipoprotein receptor; VLDL R; VLDLR; VLDL-R; VLDLRCH.
- 规格价格
- 100ul/2980元购买 大包装/询价
- 说 明 书
- 100ul
- 研究领域
- 肿瘤 心血管 免疫学 神经生物学 信号转导
- 抗体来源
- Rabbit
- 克隆类型
- Polyclonal
- 交叉反应
- Human, Mouse, Rat, Chicken, Dog, Pig, Cow, Rabbit,
- 产品应用
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
- 分 子 量
- 93kDa
- 性 状
- Lyophilized or Liquid
- 浓 度
- 1mg/ml
- 免 疫 原
- KLH conjugated synthetic peptide derived from human VLDL Receptor
- 亚 型
- IgG
- 纯化方法
- affinity purified by Protein A
- 储 存 液
- 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol
- 保存条件
- Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
- 产品介绍
- background:
VLDL (very low density lipoprotein) cholesterol is one of the three major types of cholesterol found in blood. VLDL receptor plays an essential role in triglyceride metabolism. It binds VLDL and transports it into cells by endocytosis. In order to be internalized, the receptor-ligand complexes must first cluster into clathrin coated pits. Binding to Reelin induces tyrosine phosphorylation of Dab1 and modulation of Tau phosphorylation.
Function:
Binds VLDL and transports it into cells by endocytosis. In order to be internalized, the receptor-ligand complexes must first cluster into clathrin-coated pits. Binding to Reelin induces tyrosine phosphorylation of Dab1 and modulation of Tau phosphorylation (By similarity).
Subunit:
Binds to the extracellular matrix protein Reelin. Interacts with VLDLR. Interacts with SNX17. Interacts with DAB1. Receptor for the minor-group human rhinoviruses (HRVs); binds protein VP1 through the second and third LDL-receptor class A domains.
Subcellular Location:
Membrane; Single-pass type I membrane protein. Membrane, clathrin-coated pit; Single-pass type I membrane protein.
Tissue Specificity:
Abundant in heart and skeletal muscle; also ovary and kidney; not in liver.
Post-translational modifications:
Ubiquitinated at Lys-839 by MYLIP leading to degradation.
DISEASE:
Defects in VLDLR are the cause of cerebellar ataxia mental retardation and dysequilibrium syndrome type 1 (CMARQ1) [MIM:224050]; also known as dysequilibrium syndrome (DES) or non-progressive cerebellar disorder with mental retardation. CMARQ1 is a congenital, non-progressive cerebellar ataxia associated with disturbed equilibrium, delayed ambulation, mental retardation and cerebellar hypoplasia. Additional features include short stature, strabismus, pes planus and, rarely, seizures.
Similarity:
Contains 3 EGF-like domains.
Contains 8 LDL-receptor class A domains.
Contains 6 LDL-receptor class B repeats.
Database links:Entrez Gene: 7436 Human
Entrez Gene: 22359 Mouse
Entrez Gene: 25696 Rat
Omim: 192977 Human
SwissProt: P98155 Human
SwissProt: P98156 Mouse
SwissProt: P98166 Rat
Unigene: 370422 Human
Unigene: 4141 Mouse
Unigene: 9975 Rat
Important Note:
This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.